ATON -
Two new patents have just been granted in the United States: on a key step in the chemical synthesis of inecalcitol and on its formulation as innovative tablets.
- To date, inecalcitol is protected until 2031 in Europe, the United States, Japan and eight other countries.
In addition, all the three patent families have already been granted in Europe, Russia, Singapore and New-Zealand, two of them in Japan, Israel and Mexico and one of them in China, Taiwan and Australia. The latest expiry is July 2031 in these territories, except China, Taiwan, Australia and Israel (January 2031). Examination is still pending in Canada, Brazil, India and the Republic of Korea.
The IND authorization to perform the clinical study of oral inecalcitol in the United States in acute myeloid patients unfit for chemotherapy (see Hybrigenics' press release of January 11, 2016) prompted Hybrigenics to efficiently speed up the examination process of the two remaining patent applications regarding inecalcitol pending at the USPTO.
"Our patenting strategy has been very successful in prolonging and strengthening Hybrigenics' intellectual property of inecalcitol, and in extending it worldwide until late 2031. This allows building valuable development plans and prolonged exclusivity commercialization models," said Remi Delansorne, Hybrigenics' CEO.
Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services. Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®. Inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States. A clinical Phase II study of inecalcitol is currently ongoing in chronic myeloid leukemia patients.
Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes (DUBs) and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. A first milestone has been achieved in a drug discovery program targeting one DUB in oncology.
Hybrigenics Services (www.hybrigenics-services.com) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.
Helixio (www.helixio.com), Hybrigenics' genomic branch, provides state-of-the-art services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing with an Illumina NextSeq500. Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.
Hybrigenics Rémi Delansorne CEO Tel.: +33 (0)1 58 10 38 00 investors@hybrigenics.com | NewCap Financial communication Julien Perez / Pierre Laurent Tel.: +33 (0)1 44 71 94 94 hybrigenics@newcap.eu |
Hybrigenics SA issued this content on 04 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 05 April 2016 12:09:38 UTC
